NewLimit is a biotech company developing epigenetic therapies to extend human healthspan by reprogramming aging cells.
NewLimit has raised $435.0M in total funding. The most recent round was Series C. The last funding was announced in June 2026.
NewLimit's investors include Draper Associates, Founders Fund, Khosla Ventures, Thrive Capital, Kleiner Perkins.
NewLimit is headquartered in South San Francisco, United States.
NewLimit is a biotech company developing epigenetic therapies to extend human healthspan by reprogramming aging cells.
NewLimit is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NewLimit — Funding & Investors." VCBacked, June 2, 2026, https://www.vcbacked.co/company/newlimit. Accessed August 13, 2026.
VCBacked. (2026). NewLimit — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/newlimit
{{cite web |title=NewLimit — Funding & Investors |url=https://www.vcbacked.co/company/newlimit |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated